Hemispherx BioPharma, Inc (NYSEMKT:HEB) making a mark on the pharma sphere

930

Dallas, Texas 09/09/2013 (Financialstrend) – Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that they will be featured as a presenting-company at the H.C Wainwright & Co LLC-sponsored 15th Annual-Rodman & Renshaw Global Investment Conference. This conference is going to be held 8-10 September in NYC at the Millennium Broadway Hotel.

The presentation

The company chairman and Chief Executive Officer, Dr William A Carter will be providing an overview of HEB’s business in the live presentation. He will also participate in one on one meetings with various investors who have registered to be attendees at the conference. The focus will also include new-data on the company’s platform technologies as they are related to the potential treatment and also to the prevention of any emerging pandemic viral-threats.

In Friday’s trading session, Hemispherx BioPharma, Inc (NYSEMKT:HEB) dipped 1.46%. The opening price of the shares was $0.23 which touched an intraday high of $0.24 and closed at $0.23. More than 0.306 million shares were traded on Friday and the average volume of shares traded over 30 days was 0.602 million. The company has a market cap of $39.42 million.

The company

HEB is a specialty pharma company. It is involved in the clinical-development of new drug-therapies that are based in various natural immune-system enhancing technologies. These are used for treating immune and viral-based chronic disorders

The company focuses on 2 core pharma technology platforms- AlferonN injection and Ampligen.

The commercial focus of the latter includes the application as a CFS treatment and also as an influenza-vaccine enhancer for preventive and therapeutic vaccine development. AlferonN is a U.S FDA approved product and is used in the treatment of recurring or refractory genital warts. The company has three different subsidiaries- Core BioTech Corp, BioAegean Corp and BioPro Corp. Hemispherx Biopharma Europe N.V is its foreign subsidiary. HEB competes with GlaxoSmithkline, Pfizer, Merck, Immunotherapeutics, Baxter International and Genta amongst others.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.